Bausch Health Companies Inc. (BHC): Price and Financial Metrics
BHC Price/Volume Stats
| Current price | $6.99 | 52-week high | $10.23 |
| Prev. close | $7.12 | 52-week low | $4.00 |
| Day low | $6.97 | Volume | 1,148,956 |
| Day high | $7.15 | Avg. volume | 4,626,013 |
| 50-day MA | $7.38 | Dividend yield | N/A |
| 200-day MA | $7.35 | Market Cap | 2.53B |
BHC Stock Price Chart Interactive Chart >
BHC POWR Grades
- Growth is the dimension where BHC ranks best; there it ranks ahead of 98.03% of US stocks.
- The strongest trend for BHC is in Stability, which has been heading up over the past 179 days.
- BHC's current lowest rank is in the Sentiment metric (where it is better than 1.95% of US stocks).
BHC Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for BHC is -10.19 -- better than just 1.78% of US stocks.
- BHC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 0.74% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BHC comes in at 57.64% -- higher than that of 96.69% of stocks in our set.
- Stocks that are quantitatively similar to BHC, based on their financial statements, market capitalization, and price volatility, are CCLP, SMFL, MGI, WTI, and RGS.
- BHC's SEC filings can be seen here. And to visit BAUSCH HEALTH COMPANIES INC's official web site, go to www.bauschhealth.com.
BHC Valuation Summary
- In comparison to the median Healthcare stock, BHC's price/earnings ratio is 135.68% lower, now standing at -8.6.
- Over the past 243 months, BHC's price/earnings ratio has gone down 91.3.
Below are key valuation metrics over time for BHC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BHC | 2023-05-23 | 0.4 | -3.8 | -8.6 | 18.9 |
| BHC | 2023-05-22 | 0.4 | -4.0 | -9.0 | 19.1 |
| BHC | 2023-05-19 | 0.4 | -3.8 | -8.5 | 18.9 |
| BHC | 2023-05-18 | 0.4 | -3.9 | -8.7 | 19.0 |
| BHC | 2023-05-17 | 0.3 | -3.4 | -7.6 | 18.7 |
| BHC | 2023-05-16 | 0.3 | -2.7 | -6.1 | 18.2 |
BHC Growth Metrics
- Its year over year net cashflow from operations growth rate is now at -28.85%.
- Its year over year price growth rate is now at -66.36%.
- The 3 year revenue growth rate now stands at -0.9%.
The table below shows BHC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 8,127 | -1,179 | 254 |
| 2022-06-30 | 8,192 | 648 | 43 |
| 2022-03-31 | 8,325 | 920 | -407 |
| 2021-12-31 | 8,434 | 1,426 | -948 |
| 2021-09-30 | 8,451 | 1,796 | -1,170 |
| 2021-06-30 | 8,478 | 1,488 | -1,287 |
BHC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BHC has a Quality Grade of C, ranking ahead of 53.93% of graded US stocks.
- BHC's asset turnover comes in at 0.276 -- ranking 162nd of 680 Pharmaceutical Products stocks.
- CCXI, NBY, and LLY are the stocks whose asset turnover ratios are most correlated with BHC.
The table below shows BHC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.276 | 0.714 | -0.004 |
| 2021-03-31 | 0.259 | 0.714 | 0.006 |
| 2020-12-31 | 0.255 | 0.720 | 0.022 |
| 2020-09-30 | 0.250 | 0.721 | -0.017 |
| 2020-06-30 | 0.252 | 0.725 | -0.021 |
| 2020-03-31 | 0.265 | 0.729 | -0.011 |
BHC Price Target
For more insight on analysts targets of BHC, see our BHC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $36.08 | Average Broker Recommendation | 1.62 (Moderate Buy) |
Bausch Health Companies Inc. (BHC) Company Bio
Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
Latest BHC News From Around the Web
Below are the latest news stories about BAUSCH HEALTH COMPANIES INC that investors may wish to consider to help them evaluate BHC as an investment opportunity.
Why Bausch Health Companies Stock Is Tanking TodayShares of Bausch Health Companies (NYSE: BHC) were down by 11.3% on sky-high volume as of 10:56 a.m. ET Tuesday morning. The big loss came after the drugmaker announced that the Food and Drug Administration (FDA) tentatively approved the abbreviated new drug application (ANDA) from Norwich Pharmaceuticals for the irritable bowel syndrome medication Xifaxan on June 2, 2023. In its June 2, 2023 letter, the FDA reportedly reaffirmed this later date as the benchmark for final approval. |
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug AdministrationBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg. At the same time, the FDA confirmed in its Letter that it cannot grant Final Approval until Oct. |
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum DiseaseBausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover Your Bases campaign includes educational content about the disease and encourages patients to talk to their dentist about comprehensive treatment options. The campaign launch is timed to Oral Health Month recognized throughout June a |
Top 10 Billionaire Stocks From 10 BillionairesIn this article, we will take a look at the top 10 billionaire stocks from 10 billionaires. To see more such companies, go directly to Top 5 Billionaire Stocks From 5 Billionaires. If you want to become a billionaire, do what billionaires do. This is perhaps the most truthful cliché statements that hold true irrespective […] |
15 Best Stocks to Buy and Hold According to Billionaire Carl IcahnIn this article, we discuss 15 best stocks to buy and hold according to billionaire Carl Icahn. If you want to see more stocks in this selection, check out 5 Best Stocks to Buy and Hold According to Billionaire Carl Icahn. Carl Icahn, recognized for his expertise in the financial market, faced another blow on […] |
BHC Price Returns
| 1-mo | 19.28% |
| 3-mo | -12.95% |
| 6-mo | -8.39% |
| 1-year | -22.33% |
| 3-year | -65.92% |
| 5-year | -72.90% |
| YTD | 11.31% |
| 2022 | -77.25% |
| 2021 | 32.74% |
| 2020 | -30.48% |
| 2019 | 61.99% |
| 2018 | -11.12% |
Continue Researching BHC
Want to do more research on Bausch Health Companies Inc's stock and its price? Try the links below:Bausch Health Companies Inc (BHC) Stock Price | Nasdaq
Bausch Health Companies Inc (BHC) Stock Quote, History and News - Yahoo Finance
Bausch Health Companies Inc (BHC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...